Publications

  1. Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR. Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes. Gastroenterology. 2014 Oct 08.
    View PubMed
  2. Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA. Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival. Gastroenterology. 2014 Sep 30.
    View PubMed
  3. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014 Jul; 106(7). Epub 2014 Jun 12.
    View PubMed
  4. Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res. 2014 Jun 15; 20(12):3319-27. Epub 2014 Apr 11.
    View PubMed
  5. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). Clin Cancer Res. 2014 Jun 1; 20(11):3033-43. Epub 2014 Mar 31.
    View PubMed
  6. Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, Alliance for Comparison of FOLFIRI with or without cetuximab in patients with resected stage iii colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014 Jun; 13(2):100-9. Epub 2013 Dec 28.
    View PubMed
  7. Tougeron D, Sha D, Manthravadi S, Sinicrope FA. Aspirin and colorectal cancer: back to the future. Clin Cancer Res. 2014 Mar 1; 20(5):1087-94. Epub 2013 Dec 10.
    View PubMed
  8. Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 2014 Feb 1; 120(3):415-24. Epub 2013 Oct 21.
    View PubMed
  9. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014 Jan; 232(2):199-209.
    View PubMed
  10. Ding H, McDonald JS, Yun S, Schneider PA, Peterson KL, Flatten KS, Loegering DA, Oberg AL, Riska SM, Huang S, Sinicrope FA, Adjei AA, Karp JE, Meng XW, Kaufmann SH. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica. 2014 Jan; 99(1):60-9. Epub 2013 Aug 30.
    View PubMed
  11. Graves KD, Sinicrope PS, Esplen MJ, Peterson SK, Patten CA, Lowery J, Sinicrope FA, Nigon SK, Borgen J, Gorin SS, Keogh LA, Lindor NM. Communication of genetic test results to family and health-care providers following disclosure of research results. Genet Med. 2014; 16(4):294-301.
  12. Park JM, Tougeron D, Huang S, Okamoto K, Sinicrope FA. Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells. PLoS One. 2014; 9(6):e100819. Epub 2014 Jun 23
    View PubMed
  13. Huang S, Okamoto K, Yu C, Sinicrope FA. p62/sequestosome-1 up-regulation promotes ABT-263-induced caspase-8 aggregation/activation on the autophagosome. J Biol Chem. 2013 Nov 22; 288(47):33654-66. Epub 2013 Oct 11.
    View PubMed
  14. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013 Oct 10; 31(29):3664-72. Epub 2013 Sep 09.
    View PubMed
  15. Sinicrope FA, Smyrk TC, Tougeron D, Thibodeau SN, Singh S, Muranyi A, Shanmugam K, Grogan TM, Alberts SR, Shi Q. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer. 2013 Aug 1; 119(15):2765-70. Epub 2013 May 08.
    View PubMed
  16. Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol. 2013 Jul; 11(7):760-7; quiz e54-5. Epub 2012 Dec 23.
    View PubMed
  17. Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013 Apr 15; 119(8):1528-36. Epub 2013 Jan 10.
    View PubMed
  18. Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther. 2013 Feb; 14(2):100-7. Epub 2012 Nov 28
    View PubMed
  19. Stanton MJ, Dutta S, Zhang H, Polavaram NS, Leontovich AA, Honscheid P, Sinicrope FA, Tindall DJ, Muders MH, Datta K. Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res. 2013 Jan 1; 73(1):160-71. Epub 2012 Nov 13.
    View PubMed
  20. Park JM, Huang S, Tougeron D, Sinicrope FA. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One. 2013; 8(5):e65369. Epub 2013 May 28.
    View PubMed
  21. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012 Nov 10; 30(32):3932-8. Epub 2012 Sep 17.
    View PubMed
  22. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012 Apr 4; 307(13):1383-93.
    View PubMed
  23. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.
    View PubMed
  24. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012 Mar 15; 18(6):1506-12. Epub 2012 Feb 02.
    View PubMed
  25. Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012 Feb 1; 30(4):406-12. Epub 2011 Dec 27.
    View PubMed
  26. Sinicrope PS, Goode EL, Limburg PJ, Vernon SW, Wick JB, Patten CA, Decker PA, Hanson AC, Smith CM, Beebe TJ, Sinicrope FA, Lindor NM, Brockman TA, Melton LJ 3rd, Petersen GM. A population-based study of prevalence and adherence trends in average risk colorectal cancer screening, 1997 to 2008. Cancer Epidemiol Biomarkers Prev. 2012 Feb; 21(2):347-50. Epub 2011 Dec 05.
    View PubMed
  27. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15; 18(2):546-54.
    View PubMed
  28. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012; 10:205. Epub 2012 Oct 03.
    View PubMed
  29. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One. 2012; 7(8):e42274. Epub 2012 Aug 06.
    View PubMed
  30. Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope FA. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 1; 29(34):4561-7. Epub 2011 Oct 11.
    View PubMed
  31. Huang S, Yang ZJ, Yu C, Sinicrope FA. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J Biol Chem. 2011 Nov 18; 286(46):40002-12. Epub 2011 Sep 23.
    View PubMed
  32. Winawer SJ, Pasricha PJ, Schmiegel W, Sinicrope FA, Sung J, Seufferlein T, Kassem AM, Malekzadeh R, Kurtz RC, Classen M, Tytgat GN. The future role of the gastroenterologist in digestive oncology: an international perspective. Gastroenterology. 2011 Oct; 141(4):e13-21. Epub 2011 Aug 24.
    View PubMed
  33. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011 Sep; 10(9):1533-41. Epub 2011 Aug 30.
    View PubMed
  34. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011 Jun 8; 103(11):863-75. Epub 2011 May 19.
    View PubMed
  35. Sinicrope FA, Broaddus R, Joshi N, Gerner E, Half E, Kirsch I, Lewin J, Morlan B, Hong WK. Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. Cancer Prev Res (Phila). 2011 Jun; 4(6):829-39.
    View PubMed
  36. Sinicrope FA, Yang ZJ. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol. 2011 Mar; 7(3):467-74.
    View PubMed
  37. Yang ZJ, Chee CE, Huang S, Sinicrope F. Autophagy modulation for cancer therapy. Cancer Biol Ther. 2011 Jan 15; 11(2):169-76.
    View PubMed
  38. Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010 Dec; 85(12):1080-9.
    View PubMed
  39. Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am. 2010 Sep; 39(3):601-13.
    View PubMed
  40. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 Jul 10; 28(20):3219-26. Epub 2010 May 24.
    View PubMed
  41. Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Smyrk TC, O'Connell MJ, North Central Cancer Treatment Group. Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer. 2010 Apr 1; 116(7):1691-8.
    View PubMed
  42. Sinicrope FA, Foster NR, Sargent DJ, O'Connell MJ, Rankin C. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010 Mar 15; 16(6):1884-93. Epub 2010 Mar 09.
    View PubMed
  43. Smoot RL, Blechacz BR, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, Gores GJ. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res. 2010 Mar 1; 70(5):1960-9. Epub 2010 Feb 16.
    View PubMed
  44. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol. 2010 Mar; 7(3):174-7.
    View PubMed
  45. Sinicrope FA. Opinion: DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol. 2010 Mar; 7(3):174-7.
    View PubMed
  46. Huang S, Sinicrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther. 2010 Mar; 9(3):742-50. Epub 2010 Mar 02.
    View PubMed
  47. Huang S, Sinicrope FA. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy. 2010 Feb; 6(2):256-69. Epub 2010 Feb 06.
    View PubMed
  48. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer. 2010 Jan 5; 102(1):165-72. Epub 2009 Dec 08.
    View PubMed
  49. Masuoka HC, Sinicrope FA. Clinical relevance of apoptotic regulatory proteins in colorectal cancers. Current Colorectal Cancer Reports. 2010; 6(3):111-7.
  50. Sugumar A, Sinicrope FA. Serrated polyps of the colon. F1000 Med Rep. 2010; 2:89. Epub 2010 Dec 17.
    View PubMed
  51. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009 Oct; 137(4):1270-9. Epub 2009 Jul 03.
    View PubMed
  52. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol. 2009 Jul; 21(4):369-73.
    View PubMed
  53. Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res. 2009 Jan 1; 15(1):150-9.
    View PubMed
  54. Okumura K, Huang S, Sinicrope FA. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res. 2008 Dec 15; 14(24):8132-42.
    View PubMed
  55. Sinicrope FA, Rego RL, Okumura K, Foster NR, O'Connell MJ, Sargent DJ, Windschitl HE. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res. 2008 Sep 15; 14(18):5810-8.
    View PubMed
  56. Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE, Sargent DJ. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res. 2008 Jul 1; 14(13):4128-33.
    View PubMed
  57. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008 Apr 15; 68(8):2944-51.
    View PubMed
  58. Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, Alberts SR, Murray JA, Zinsmeister AR, Vazquez-Sequeiros E, Nichols FC 3rd, Miller RC, Quevedo JF, Allen MS, Alexander JA, Zais T, Haddock MG, Romero Y. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus. 2008; 21(3):241-50.
    View PubMed
  59. Half E, Sun Y, Sinicrope FA. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Lett. 2007 Jun 28; 251(2):237-46. Epub 2006 Dec 26.
    View PubMed
  60. Sinicrope FA, Rego RL, Garrity-Park MM, Foster NR, Sargent DJ, Goldberg RM, Wiesenfeld M, Witzig TE, Thibodeau SN, Burgart LJ. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer. 2007 Mar 15; 120(6):1232-8.
    View PubMed
  61. Half E, Sinicrope FA. Current status of colorectal cancer chemoprevention. Current Colorectal Cancer Reports. 2007; 3(1):39-48.
  62. Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE, Thibodeau SN. Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol. 2006 Dec; 101(12):2818-25. Epub 2006 Oct 06.
    View PubMed
  63. Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, French AJ, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology. 2006 Sep; 131(3):729-37.
    View PubMed
  64. Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):808-21. Epub 2006 Jun 22.
    View PubMed
  65. Cohen G, Mustafi R, Chumsangsri A, Little N, Nathanson J, Cerda S, Jagadeeswaran S, Dougherty U, Joseph L, Hart J, Yerian L, Tretiakova M, Yuan W, Obara P, Khare S, Sinicrope FA, Fichera A, Boss GR, Carroll R, Bissonnette M. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res. 2006 Jun 1; 66(11):5656-64.
    View PubMed
  66. Sinicrope FA. Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog. 2006 Jun; 45(6):447-54.
    View PubMed
  67. Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, La Plant B, French AJ, Allegra CJ, Laurie JA, Goldberg RM, Witzig TE, Thibodeau SN. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res. 2006 May 1; 12(9):2738-44.
    View PubMed
  68. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem. 2006 Apr 28; 281(17):11923-32. Epub 2006 Jan 30.
    View PubMed
  69. Sinicrope FA, Penington RC. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther. 2005 Oct; 4(10):1475-83.
    View PubMed
  70. Alberts SR, Sinicrope FA, Grothey A. N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer. 2005 Sep; 5(3):211-3.
    View PubMed
  71. Gill S, Sinicrope FA. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol. 2005 Feb; 32(1):24-34.
    View PubMed
  72. Sun Y, Sinicrope FA. Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol Cancer Ther. 2005 Jan; 4(1):51-9.
    View PubMed
  73. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res. 2004 Dec 15; 10(24):8284-92.
    View PubMed
  74. Wargovich MJ, Chang P, Velasco M, Sinicrope F, Eisenbrodt E, Sellin J. Expression of cellular adhesion proteins and abnormal glycoproteins in human aberrant crypt foci. Appl Immunohistochem Mol Morphol. 2004 Dec; 12(4):350-5.
    View PubMed
  75. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC, Familial Adenomatous Polyposis Study Group. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):920-7.
    View PubMed
  76. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004 Feb 10; 108(4):540-8.
    View PubMed
  77. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Reviews. 2004 Jan-Jun; 23(1-2):63-75.
    View PubMed
  78. Sun YJ, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002 Nov 1; 62(21):6323-8.
    View PubMed
  79. Bismar MM, Sinicrope FA. Radiation enteritis. Curr Gastroenterol Rep. 2002 Oct; 4(5):361-5.
    View PubMed
  80. Tang XM, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002 Sep 1; 62(17):4903-8.
    View PubMed
  81. Sinicrope FA, Gwyn K. Chemoprevention of colorectal cancer. Am J Gastroenterol. 2002; 97:13-21.
    View PubMed
  82. Tatabe S, Unate H, Sinicrope FA, Sakatani T, Sugamura K, Makino M, Ito H, Savaraj N, Kaibara N, Kuo MT. Expression of heavy subunit of y-Glutamylcysteine synthetase (y-GCSh) in human colorectal carcinoma. Int J Cancer. 2002; 97:21-7.
    View PubMed
  83. Sample D, Sinicrope PS, Wargovich MJ, Sinicrope FA. Post study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2002; 11:281-5.
    View PubMed
  84. Sample D, Wargovich MJ, Fischer SM, Inamdar N, Schwartz P, Wang X, Do, K-A, Sinicrope FA. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal PGE2 levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 2002; 11:275-9.
    View PubMed
  85. Tatabe S, Sinicrope FA, Kuo MT. Induction of multidrug resistance protein MRP1and MRP3 and y-glutamylcystein synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002; 290:1427-33.
    View PubMed
  86. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002; 62:1676-81.
    View PubMed
  87. Boland CR, Sinicrope FA, Brenner D, Carethers J. Colorectal cancer prevention and treatment. Gastroenterology. 2000; 118:S115-S28.
    View PubMed
  88. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa J-P. Aberrant methylation of the COX-2 CpG island in colorectal tumors. Cancer Res. 2000; 60:4044-8.
    View PubMed
  89. Frazier ML, Sinicrope FA, Amos CI, Cleary KR, Lynch PM, Luthra R. Loci for efficient detection of microsatellite instability in hereditary nonpolyposis colorectal cancer. Oncology Reports. 1999; 6:497-505.
    View PubMed
  90. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Chiao PJ, Abbruzzese JL, Evans DB. Prognostic factors in resectable pancreatic cancer: P53 and bcl-2. J Gastrointest Surg. 1999; 3:263-77.
    View PubMed
  91. Sinicrope FA, Hart J, Lemoine M, Michelassi F, Lee JJ, Stephens LC. Apoptotic and mitotic indices predict patient survival rates in lymph node-negative colon carcinomas. Clin Cancer Res. 1999; 5:1793-804.
    View PubMed
  92. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase-2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology. 1999; 117:350-8.
    View PubMed
  93. Molina M, Anja-Buta M, Lemoine M, Xi L, Frazier M, Sinicrope FA. Increased cyclooxygenase-2 expression in pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999; 59:4356-62.
    View PubMed
  94. Sinicrope FA, Roddey GR, McDonnell TJ, Shen Y, Stephens LC. Increased apoptosis accompanies neoplastic development in the human colorectum. Clin Cancer Res 1996 06. 1999-20; 2:1999-2006.
  95. Sinicrope FA, Roddey GR, LeMoine M, Frazier M, Stephens LC, Shen Y, Zhang W. Loss of p21WAF1/Cip1 protein expression accompanies neoplastic progression in the sporadic colorectal cancers but not HNPCCs. Clin Cancer Res. 1998; 4:1251-61.
    View PubMed
  96. Sinicrope FA, Evans DB, Leach S, Cleary KR, Rich TA, Fenoglio C, Lee JJ, Abbruzzese JL. Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996; 2:2015-22.
    View PubMed
  97. Sinicrope FA, Pazdur R, Levin B. Phase I evaluation of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy of colon carcinoma. Clin Cancer Res. 1996; 2:37-41.
    View PubMed
  98. Al-Sabbagh R, Sinicrope FA, Sellin J, Roubein L. Short-chain fatty acid enemas: treatment of radiation proctitis. Am J Gastroenterol. 1996; 91:1814-16.
    View PubMed
  99. Roubein LD, Lynch PM, Glober G, Sinicrope FA. Interobserver variability in endoscopic ultrasonography: a prospective evaluation. Gastrointest Endosc. 1996; 5:573-7.
  100. Sinicrope FA, Ruan S, Cleary KR, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995; 55:237-41.
    View PubMed
  101. Sinicrope FA, Sugarman S. Role of adjuvant therapy in surgically resected colorectal carcinoma. Gastroenterology. 1995; 109:984-93.
    View PubMed
  102. Weber D, Dimopoulos M, Sinicrope FA, Alexanian R. VAD-cyclosporin therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1995; 19:159-63.
    View PubMed
  103. Sinicrope FA, Hart J, Michelassi FM, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995; 1:1103-10.
    View PubMed
  104. Sinicrope FA, Levin B. Gastric cancer. Curr Opin in Gastroenterol. 1994; 10:610-17.
  105. Sinicrope FA, Sugarman SM. Adjuvant therapy of colon carcinoma: current status and future directions. Cancer Bull. 1994; 46:344-51.
  106. Sinicrope FA, Hart J, Michelassi F, Safa AR, Lee JJ, Brasitus TA. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer. 1994; 74:2908-17.
    View PubMed
  107. Sinicrope FA, Levin B. Gastric cancer. Curr Opin in Gastroenterol. 1993; 9:930-7.
  108. Kavin H, Sinicrope FA, Esker AH. Perforation of the colon at endoscopy: a review. Am J Gastroenterology. 1992; 87:161-7.
  109. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P- glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem. 1992; 267:24995-5002.
    View PubMed